<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03813810</url>
  </required_header>
  <id_info>
    <org_study_id>Air_pollution_cohort</org_study_id>
    <nct_id>NCT03813810</nct_id>
  </id_info>
  <brief_title>Impact of Air Pollution on Chronic Respiratory Diseases</brief_title>
  <official_title>The Impact of Air Pollution on Chronic Respiratory Diseases: a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Medical Center, Seoul</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KangWon National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the impact of air pollution on the occurrence and&#xD;
      clinical course of chronic respiratory diseases, and discover new biomarkers from various&#xD;
      devices such as CT images that can indicate the process and amount of lung damage caused by&#xD;
      air pollution.&#xD;
&#xD;
      Accordingly, the investigators have designed an prospective cohort with enrollment of normal&#xD;
      people and patients with chronic respiratory diseases of three different categories (chronic&#xD;
      obstructive pulmonary disease, asthma, idiopathic pulmonary fibrosis). Participants will be&#xD;
      followed up for a period of one year, with evaluation of the clinical course of the&#xD;
      respiratory disease and exposure to air pollution.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Normal people (n=90) and patients with chronic respiratory diseases (chronic obstructive&#xD;
      pulmonary disease, asthma, idiopathic pulmonary fibrosis, n=90 for each disease) will be&#xD;
      enrolled at 5 different institutions in South Korea and followed up for one year.&#xD;
      Inspiratory-expiratory CTs and tests including physical examination and blood/urine tests&#xD;
      would be performed at the time of enrollment and the time at completion of the follow up&#xD;
      period for each participant. Participants would be checked for the residency and working&#xD;
      places, as well as checked for the amount of air pollution exposure using a wearable&#xD;
      measurement device for 5 days during the study period ( time at enrollment / 3 months / 6&#xD;
      months / 9 months / time at completion). The device would cause no effect on usual daily life&#xD;
      or the medical status of the participant. The clinical course such as occurrence of disease,&#xD;
      acute exacerbation, decline of lung function, imaging status, mortality would be evaluated as&#xD;
      well as the exposure of air pollution for each individual.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 25, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of mortality</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Events of mortality through study completion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of acute exacerbations</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Events of acute exacerbations through study completion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of disease extent in CT imaging</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Emphysema index (0-100, higher values representing worse outcome)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lung function</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>FEV1 (forced expiratory volume at one second, 10-150 %, lower values representing worse outcome)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in symptom scor</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>St. George's Respiratory Questionnaire score (0-100, higher values representing worse outcome)</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Asthma</condition>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <description>People without any chronic pulmonary diseases.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic obstructive pulmonary disease</arm_group_label>
    <description>Patients with chronic obstructive pulmonary disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthma</arm_group_label>
    <description>Patients with asthma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idiopathic pulmonary fibrosis</arm_group_label>
    <description>Patients with idiopathic pulmonary fibrosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non</intervention_name>
    <description>There would be no interventions. Only measurements will be performed.</description>
    <arm_group_label>Asthma</arm_group_label>
    <arm_group_label>Chronic obstructive pulmonary disease</arm_group_label>
    <arm_group_label>Idiopathic pulmonary fibrosis</arm_group_label>
    <arm_group_label>Normal</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, urine, induced sputum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Normal adults and adult patients with chronic respiratory disease (chronic obstructive&#xD;
        pulmonary disease, asthma, idiopathic pulmonary fibrosis)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal: People with no lung lesions in chest X-ray and St. George's Respiratory&#xD;
             Questionnaire score &lt;25, and post bronchodilator FEV1/FVC (forced expiratory volume at&#xD;
             one second/forced vital capacity) &gt;= 0.7 and FEV1 &gt;= 80% and FVC &gt;= 80%.&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease: Patients with over 10 pack-years of smoking&#xD;
             history and post bronchodilator FEV1/FVC &lt;0.7 and FEV1 &lt; 80%, and no other reason for&#xD;
             decline of lung function.&#xD;
&#xD;
          -  Asthma: Patients with FEV1/FVC &lt; 0.85 and increase in over 12% and 200mL of FEV1 by&#xD;
             bronchodilator inhalation. Patients with P20 &lt; 16mg/dL by bronchial provocation test.&#xD;
&#xD;
          -  Idiopathic pulmonary fibrosis: Shows usual interstitial pneumonia according to chest&#xD;
             CT and has no other reasons such as systematic diseases or medication history.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who refused for enrollment in the study&#xD;
&#xD;
          -  Subjects who experienced an acute exacerbation within 1 month.&#xD;
&#xD;
          -  Subjects under age of 19.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2019</study_first_posted>
  <last_update_submitted>January 21, 2019</last_update_submitted>
  <last_update_submitted_qc>January 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

